72 related articles for article (PubMed ID: 11366728)
1. Gender difference in Nevirapine-associated rash.
Proj Inf Perspect; 1999 Apr; (27):11. PubMed ID: 11366728
[TBL] [Abstract][Full Text] [Related]
2. Desensitization to Nevirapine.
TreatmentUpdate; 1999 Nov; 11(8):5. PubMed ID: 11367044
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
Santos RP; Ramilo O; Barton T
Pediatr Infect Dis J; 2007 Nov; 26(11):1053-6. PubMed ID: 17984815
[TBL] [Abstract][Full Text] [Related]
4. Side effects. Severe nevirapine rash found more likely in women than men.
TreatmentUpdate; 2001; 12(8):7. PubMed ID: 12132442
[No Abstract] [Full Text] [Related]
5. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
Bourezane Y; Salard D; Hoen B; Vandel S; Drobacheff C; Laurent R
Clin Infect Dis; 1998 Nov; 27(5):1321-2. PubMed ID: 9827291
[No Abstract] [Full Text] [Related]
6. Nevirapine hypersensitivity.
Popovic M; Shenton JM; Chen J; Baban A; Tharmanathan T; Mannargudi B; Abdulla D; Uetrecht JP
Handb Exp Pharmacol; 2010; (196):437-51. PubMed ID: 20020271
[TBL] [Abstract][Full Text] [Related]
7. HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
Gatanaga H; Yazaki H; Tanuma J; Honda M; Genka I; Teruya K; Tachikawa N; Kikuchi Y; Oka S
AIDS; 2007 Jan; 21(2):264-5. PubMed ID: 17197830
[No Abstract] [Full Text] [Related]
8. Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
Raffi F; Lewden C; Chêne G
AIDS; 2008 Jan; 22(3):435-6. PubMed ID: 18195573
[No Abstract] [Full Text] [Related]
9. Sex differences in adverse reactions to antiretroviral drugs.
Ofotokun I; Pomeroy C
Top HIV Med; 2003; 11(2):55-9. PubMed ID: 12717043
[TBL] [Abstract][Full Text] [Related]
10. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness also in general practice conditions. Just as good in routine practice as in studies].
MMW Fortschr Med; 2000; 142(3 Suppl):36-7. PubMed ID: 10893965
[No Abstract] [Full Text] [Related]
12. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
Littera R; Carcassi C; Masala A; Piano P; Serra P; Ortu F; Corso N; Casula B; La Nasa G; Contu L; Manconi PE
AIDS; 2006 Aug; 20(12):1621-6. PubMed ID: 16868443
[TBL] [Abstract][Full Text] [Related]
13. Risk for immune-mediated liver reactions by nevirapine revisited.
Medrano J; Barreiro P; Tuma P; Vispo E; Labarga P; Blanco F; Soriano V
AIDS Rev; 2008; 10(2):110-5. PubMed ID: 18615121
[TBL] [Abstract][Full Text] [Related]
14. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
Sanne I; Mommeja-Marin H; Hinkle J; Bartlett JA; Lederman MM; Maartens G; Wakeford C; Shaw A; Quinn J; Gish RG; Rousseau F
J Infect Dis; 2005 Mar; 191(6):825-9. PubMed ID: 15717255
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
16. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
18. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in nevirapine rash.
Bersoff-Matcha SJ; Miller WC; Aberg JA; van Der Horst C; Hamrick HJ; Powderly WG; Mundy LM
Clin Infect Dis; 2001 Jan; 32(1):124-9. PubMed ID: 11118391
[TBL] [Abstract][Full Text] [Related]
20. Third-trimester maternal toxicity with nevirapine use in pregnancy.
Joy S; Poi M; Hughes L; Brady MT; Koletar SL; Para MF; Fan-Havard P
Obstet Gynecol; 2005 Nov; 106(5 Pt 1):1032-8. PubMed ID: 16260522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
